Saturday 17 October 2026
Export SSII’s income statement to Excel — free account
SS Innovations International, Inc.
SSII Healthcare Medical Devices
SS Innovations International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $42.5 million, up 105.7% from fiscal 2024. In the quarter to June 2026, revenue grew 39.4%, EPS fell 669.2%, free cash flow fell 16.6% and total debt rose 109.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
2.55
0.03
−1.16%
Follow SSII
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
15.85 | 20.22 | 25.40 | 34.89 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(196.14) | (423.91) | (710.22) | (168.50) | |
P/B ratio |
15.55 | 17.97 | 28.24 | 31.74 | |
Price to Tangible BV |
15.57 | 17.99 | 28.27 | 31.77 | |
EV/Sales |
15.70 | 19.96 | 25.46 | 34.84 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(52.98) | (65.59) | (58.33) | (61.95) | |
EV/FCF |
(45.17) | (55.00) | (48.71) | (56.22) | |
Quick Ratio |
1.23 | 1.45 | 0.82 | 0.88 | |
Current Ratio |
2.24 | 2.54 | 1.86 | 2.29 | |
Net Debt/EBITDA |
3.98 | 3.76 | (10.24) | 1.06 | |
Debt/Assets |
15.09% | 12.32% | 15.42% | 14.47% | |
Debt/Equity |
0.27 | 0.20 | 0.30 | 0.25 | |
Asset Turnover |
0.63 | 0.63 | 0.73 | 0.67 | |
Operating CF/Net income |
1.59 | 0.65 | 0.61 | 2.01 | |
Capex/Depreciation |
(0.46) | (0.17) | (5.54) | (2.54) | |
Interest Coverage |
(6.59) | (12.81) | (1.59) | (10.39) | |
Research and Development Expense of Revenue |
17.19% | 8.97% | 9.57% | 6.13% | |
Selling, General and Administrative Expense of Revenue |
47.56% | 68.88% | 35.85% | 53.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.95% | 28.32% | 13.92% | 16.33% | |
Graham Net Nets |
0.03 | 0.03 | 0.01 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.45%) | (1.03%) | (1.08%) | (0.96%) | |
Free Cash Flow Yield |
(2.19%) | (1.80%) | (2.06%) | (1.78%) | |
Revenue per Share |
0.07 | 0.06 | 0.08 | 0.07 | |
Operating CF per Share |
(0.02) | (0.01) | (0.01) | (0.04) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.01) | (0.02) | (0.04) | |
Cash per Share |
0.11 | 0.12 | 0.05 | 0.06 | |
Shareholders Equity per Share |
0.27 | 0.28 | 0.20 | 0.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.27 | 0.28 | 0.20 | 0.20 | |
Free Cash Flow |
(4.40) | (2.37) | (3.23) | (8.22) | |
Working Capital |
39.56 | 40.22 | 22.53 | 27.24 | |
Capital Expenditures |
(0.16) | (0.05) | (1.71) | (0.75) | |
Net Current Asset Value |
27.87 | 30.24 | 12.77 | 18.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.12 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.48 | 9.01 | 8.43 | 6.01 | |
Average Payables |
5.67 | 4.02 | 3.72 | 3.26 | |
Average Inventory |
18.37 | 15.68 | 13.64 | 14.61 | |
Average Assets |
83.48 | 77.00 | 58.31 | 53.69 | |
Average Common Equity |
47.71 | 47.54 | 25.84 | 26.77 |
Columns are period end dates